NO20060612L - Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren - Google Patents

Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren

Info

Publication number
NO20060612L
NO20060612L NO20060612A NO20060612A NO20060612L NO 20060612 L NO20060612 L NO 20060612L NO 20060612 A NO20060612 A NO 20060612A NO 20060612 A NO20060612 A NO 20060612A NO 20060612 L NO20060612 L NO 20060612L
Authority
NO
Norway
Prior art keywords
compounds
oxazolidin
azabicyclo
spiro
octane
Prior art date
Application number
NO20060612A
Other languages
English (en)
Norwegian (no)
Inventor
Eifion Phillips
Hui-Fang Chang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060612L publication Critical patent/NO20060612L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20060612A 2003-07-08 2006-02-08 Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren NO20060612L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48552303P 2003-07-08 2003-07-08
PCT/GB2004/002904 WO2005005435A1 (en) 2003-07-08 2004-07-06 Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor

Publications (1)

Publication Number Publication Date
NO20060612L true NO20060612L (no) 2006-04-06

Family

ID=34062082

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060612A NO20060612L (no) 2003-07-08 2006-02-08 Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren

Country Status (17)

Country Link
US (1) US7514567B2 (https=)
EP (1) EP1654264A1 (https=)
JP (1) JP2007516200A (https=)
KR (1) KR20060057569A (https=)
CN (1) CN1829721A (https=)
AR (1) AR045040A1 (https=)
AU (1) AU2004255920B2 (https=)
BR (1) BRPI0412382A (https=)
CA (1) CA2531510A1 (https=)
IL (1) IL172762A0 (https=)
MX (1) MXPA06000231A (https=)
NO (1) NO20060612L (https=)
NZ (1) NZ545132A (https=)
SA (1) SA04250212B1 (https=)
TW (1) TW200524942A (https=)
WO (1) WO2005005435A1 (https=)
ZA (1) ZA200600154B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070090922A (ko) * 2004-12-15 2007-09-06 아스트라제네카 아베 니코틴성 아세틸콜린 수용체 리간드
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
WO2008021337A1 (en) * 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
JP2010505844A (ja) * 2006-10-03 2010-02-25 ガレオン・フアーマシユーチカルズ・インコーポレーテツド S−ニトロソチオール化合物および関連誘導体
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US7863291B2 (en) * 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
EP2586311B1 (de) * 2008-07-17 2016-12-14 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
UA107791C2 (en) * 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
US8759550B2 (en) 2009-08-27 2014-06-24 Yeda Research And Development Co. Ltd. Oligo- and polyfurans, preparation and uses thereof
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8507516B2 (en) 2009-10-28 2013-08-13 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
EP2558458B1 (de) 2010-04-16 2017-09-06 Bayer Intellectual Property GmbH Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
EP2595983A1 (en) 2010-07-22 2013-05-29 Novartis AG 2,3,5-trisubstituted thiophene compounds and uses thereof
WO2012052412A1 (de) 2010-10-22 2012-04-26 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
KR20140138293A (ko) 2012-03-16 2014-12-03 액시킨 파마수티컬스 인코포레이티드 3,5-다이아미노피라졸 키나아제 억제제
CN104884449A (zh) 2012-10-31 2015-09-02 拜尔农作物科学股份公司 作为害虫防治剂的新的杂环化合物
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
WO2001066546A1 (en) * 2000-03-09 2001-09-13 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs

Also Published As

Publication number Publication date
BRPI0412382A (pt) 2006-09-19
AU2004255920A1 (en) 2005-01-20
JP2007516200A (ja) 2007-06-21
CN1829721A (zh) 2006-09-06
KR20060057569A (ko) 2006-05-26
AU2004255920B2 (en) 2008-05-15
IL172762A0 (en) 2006-04-10
WO2005005435A1 (en) 2005-01-20
TW200524942A (en) 2005-08-01
AR045040A1 (es) 2005-10-12
ZA200600154B (en) 2007-04-25
MXPA06000231A (es) 2006-04-11
SA04250212B1 (ar) 2009-08-11
NZ545132A (en) 2009-07-31
CA2531510A1 (en) 2005-01-20
US20060154945A1 (en) 2006-07-13
US7514567B2 (en) 2009-04-07
EP1654264A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
NO20060612L (no) Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren
RU2737190C2 (ru) Ингибиторы репликации вируса гриппа, способы их применения и использование
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20055092L (no) Substituerte pyrimidioner
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BRPI0606817A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
NO20055892L (no) Karboksylsyrederivater
CA2468649A1 (en) Adenosine a2a receptor antagonists
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20064010L (no) Indazolderivater og farmasoytiske preparater inneholdelse slike
WO2002060423A3 (en) Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
EP1228072A4 (en) PDGF RECEPTOR KINASE INHIBITING COMPOUNDS, THEIR PRODUCTION, CLEANING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application